Tag Archives | SABCS 2011

Impressive results for pertuzumab in CLEOPATRA breast cancer trial

At the recent San Antonio Breast Cancer Symposium (SABCS), the clinical evaluation of pertuzumab and trastuzumab (CLEOPATRA) clinical trial results were presented by Dr José Baselga (Massachusetts General Hospital). This study combined two anti human epidermal growth factor receptor 2 (HER2) monoclonal antibodies, trastuzumab and pertuzumab with docetaxel. Results showed a median progression-free survival of 18.5 […]

Continue Reading

BOLERO-2 clinical trial of Everolimus in Advanced Breast Cancer

Updated results from the BOLERO-2 (breast cancer trials of oral everolimus) were presented at the recent San Antonio Breast Cancer Symposium (SABCS). José Baselga had previously presented the impressive results at ECCO/ESMO 2011 in Stockholm. As Sally Church noted on Pharma Strategy Blog in her second update on “what’s hot at SABCS”: “The trial data […]

Continue Reading

Insights from AACR Molecular Targets Meeting

There was a lot of interesting science at the recent AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics international conference in San Francisco. In particular, the poster sessions offered the opportunity to discuss pre-clinical and early drug development work, and share insights into pathways and mechanisms of action. If you are in new product development, it’s a […]

Continue Reading

Everolimus plus exemestane is the biggest advance in breast cancer since Herceptin

2011 European Multidisciplinary Cancer Congress Breast cancer news  There were two noteworthy breast trials with new data at the 2011 ESMO ECCO oncology congress in Stockholm this past weekend: 1) The phase III BOLERO-2 study for everolimus (Afinitor) plus exemestane is according to Sally Church, “probably the biggest single advance in breast since the Herceptin […]

Continue Reading

Conference Coverage: the week in review

Now that summer is officially over, the fall pharma/biotech conference season has started. You can find out details of the conferences Icarus Consultants will be attending by checking out our conference schedule. If you are interested in our meeting coverage services or a conference report, please contact us. This week, we followed two conferences remotely […]

Continue Reading

Potential New Triple Negative Breast Cancer Biomarkers

Sally Church on Pharma Strategy Blog has written about recent research in triple-negative breast cancer (TNBC). She discusses a published study from Vanderbilt that identified six different subtypes of the disease; each subtype being sensitive to different drug therapies. As Sally points out these subtypes could be used as a potential biomarker for patient selection […]

Continue Reading